These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18077485)

  • 21. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options.
    Svensson B; Ahlmén M; Forslind K
    Clin Exp Rheumatol; 2003; 21(3):327-32. PubMed ID: 12846051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rheumatoid arthritis: new developments in the use of existing therapies.
    O'Dell JR; Scott DL
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():24-6. PubMed ID: 10646486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy.
    Boers M;
    Arthritis Rheum; 2001 Nov; 44(11):2703-4. PubMed ID: 11710727
    [No Abstract]   [Full Text] [Related]  

  • 24. [Guidelines for RA therapies].
    Ochi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():439-43. PubMed ID: 15799395
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of rheumatoid arthritis: we are getting there.
    Yazici Y
    Lancet; 2009 Jul; 374(9685):178-80. PubMed ID: 19560809
    [No Abstract]   [Full Text] [Related]  

  • 26. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.
    Pham B; Cranney A; Boers M; Verhoeven AC; Wells G; Tugwell P
    J Rheumatol; 1999 Mar; 26(3):712-6. PubMed ID: 10090188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
    van Tuyl LH; Boers M; Lems WF; Landewé RB; Han H; van der Linden S; van de Laar M; Westhovens R; van Denderen JC; Westedt ML; Peeters AJ; Jacobs P; Huizinga TW; van de Brink H; Dijkmans BA; Voskuyl AE
    Ann Rheum Dis; 2010 May; 69(5):807-12. PubMed ID: 19451137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
    Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
    Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission as the treatment goal--the FIN-RACo trial.
    Sokka T; Mäkinen H; Puolakka K; Möttönen T; Hannonen P
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-74-6. PubMed ID: 17083766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rheumatoid arthritis.
    Emery P; Suarez-Almazor M
    Clin Evid; 2003 Jun; (9):1349-71. PubMed ID: 15366179
    [No Abstract]   [Full Text] [Related]  

  • 31. American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement.
    Boers M; Verhoeven AC; van der Linden S
    Arthritis Rheum; 2001 May; 44(5):1052-5. PubMed ID: 11352236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
    D'Arcy CA; Willkens RF
    J Rheumatol; 2002 Dec; 29(12):2662; author reply 2662-3. PubMed ID: 12465172
    [No Abstract]   [Full Text] [Related]  

  • 33. Early rheumatoid arthritis treatments weighed.
    Mitka M
    JAMA; 2005 Dec; 294(24):3073-4. PubMed ID: 16380583
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of rheumatoid arthritis.
    Zurier RB; DeMarco DM; Liu NY
    N Engl J Med; 1996 Sep; 335(11):822; author reply 822-3. PubMed ID: 8778595
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
    Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam S; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF;
    Ann Rheum Dis; 2011 Mar; 70(3):469-75. PubMed ID: 21149498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis.
    Shiroky JB
    J Rheumatol Suppl; 1996 Mar; 44():69-71. PubMed ID: 8833057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Putting new disease-modifying antirheumatic drugs into perspective.
    Saseen JJ
    Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
    [No Abstract]   [Full Text] [Related]  

  • 38. [Infliximab in the treatment of rheumatoid arthritis].
    Akahoshi T; Watabe H
    Nihon Rinsho; 2002 Dec; 60(12):2378-83. PubMed ID: 12510365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of abatacept in patients with rheumatoid arthritis and no prior treatment with biologics].
    Escudero Contreras A; Castro-Villegas MC; Hernández-Hernández MV; Díaz-González F
    Reumatol Clin; 2011; 7(6):392-6. PubMed ID: 22078698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab and abatacept for rheumatoid arthritis.
    BMJ Group
    Drug Ther Bull; 2008 Aug; 46(8):57-61. PubMed ID: 18687584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.